Background
The association between thyroid hormones and the risk of breast cancer (BC) has been reported in epidemiological studies [
1,
2]. A positive association has been reported between thyroxine (T4) and risk of BC, which is more pronounced in overweight and obese women [
1]. Negative associations have been reported between triiodothyronine (T3) and BC among premenopausal women; in contrast, positive associations have been observed among postmenopausal women [
2]. It has been shown that in in vitro studies, thyroid hormones affect the growth of BC-derived cell lines [
3], lung cancer [
4], and glioblastoma [
5]. T4 has been shown to increase cell proliferation through the αvβ3 integrin receptor found on the plasma membrane of cells [
3]. In contrast, the effect of T3 on cell proliferation has not been well-established because it differs by the type of cell line used [
6‐
8]. These effects are important, since abnormalities in thyroid function tests have been observed in a variety of non-thyroidal illnesses, without preexisting thyroid or hypothalamic-pituitary disease [
9]. Furthermore, these abnormalities might change with body mass index (BMI) because thyroid hormones are involved in the regulation of various metabolic pathways (e.g., adaptive thermogenesis and glucose metabolism) that are relevant for resting energy expenditure and changes in body weight [
10,
11].
Worldwide, obesity has increased to epidemic proportions in recent years. According to the World Health Organization (WHO) in 2014, 40% of women over age 18 years were obese and 15% were overweight [
12]. By 2016, in Mexico, 37% of women older than 20 years were overweight, and the prevalence of obesity was 38.6% [
13]. Obesity has been linked to various chronic diseases and to the development of different types of cancer, including BC [
14]. One study indicated that if the BMI had remained at 1982 levels, nearly a quarter (118,000 cases) of all obesity-related cancers in 2012 could have been avoided worldwide [
15].
Obesity, as measured by BMI, has been associated with BC risk, but conflicting effects have been reported in premenopausal and postmenopausal women [
16‐
19]. In premenopausal women, BMI is associated with decreased BC risk [
20‐
27], whereas in postmenopausal women, it has been associated with an increased BC risk [
28‐
30]. Recently, genetically predicted BMI was inversely associated with BC risk in both, premenopausal and postmenopausal women [
31]. The mechanisms behind these associations have not been fully explained [
27]. Several metabolic conditions associated with body fat can influence the BC risk differently in premenopausal and postmenopausal women [
27,
32].
In a cohort study conducted in Swedish women, Tosovic et al. (2012) reported a positive association between serum concentrations of free T4 (FT4) and BC prior to diagnosis, particularly in women with a BMI ≥ 25, while for free T3 (FT3), the protective effect was higher in women with BMI < 25; however, most of the associations were not statistically significant [
1]. White adipose tissue actively produces various hormones and cytokines (e.g., leptin and growth factors, among others) [
33], which are important in the homeostasis and regulation of thyroid hormones [
34]. Several studies in euthyroid women have reported that serum free thyroxine (FT4) concentration is inversely correlated with BMI [
35‐
37], while FT3 has been positively associated with visceral fat [
38,
39] and BMI ≥ 40 [
40], negatively with body fat measured using bioimpedance [
41], and not correlated with BMI [
36].
In the present case-control study, we examined the association between serum concentrations of thyroid hormones and BC in 2074 Mexican women who participated in the Cáncer de Mama (CAMA) study. We also examined obesity as an effect modifier of this relationship in premenopausal and postmenopausal women.
Results
The characteristics of the study population are presented separately for premenopausal and postmenopausal women in Table
1. Compared to controls, premenopausal patients (cases), were more likely to have completed professional and postgraduate studies (data not shown). Among postmenopausal women, a higher percentage of patients completed secondary, high school, and postgraduate studies compared with the controls (data not shown). Parity, history of benign breast disease, physical activity, alcohol consumption, and history of diabetes mellitus are associated with BC according to the literature. In both premenopausal and postmenopausal women, waist circumference and hip circumference were smaller in the patients than in the controls. BMI was lower in the patients than in the controls. Table
2, shows that in both the premenopausal and postmenopausal women, the serum TT3 concentration was lower in the patients than in the controls, whereas the serum TT4 concentration was higher in the patients than in the controls. Table
3, shows that more than 40% of the study participants were diagnosed at an advanced clinical stage.
Table 1
Characteristics of study participants by menopausal status in the CAMA study, Mexico, 2004–2007
Sociodemographic
|
Age (years)b | 44.1 | 38.6–47.3 | 44.1 | 40.6–47.8 | 58.0 | 52.9–64.3 | 57.4 | 52.3–62.1 |
Wealth index |
Low | 52 | (35.4) | 45 | (28.3) | 155 | (31.1) | 199 | (37.0) |
Medium | 38 | (25.9) | 49 | (30.8) | 125 | (25.1) | 187 | (34.8) |
High | 57 | (38.8) | 65 | (40.9) | 218 | (43.8) | 152 | (28.3) |
Indigenous ancestry percent
|
0–25% | 3 | (2.0) | 4 | (2.5) | 21 | (4.2) | 10 | (1.9) |
26–50% | 38 | (25.9) | 41 | (25.8) | 130 | (26.1) | 125 | (23.2) |
51–75% | 49 | (33.3) | 77 | (48.4) | 188 | (37.8) | 245 | (45.5) |
76–100% | 18 | (12.2) | 33 | (20.8) | 79 | (15.9) | 139 | (25.8) |
Reproductive health
|
Time of exposure to endogenous hormones (years)b | | | | 34 | 30–37 | 34 | 29–37 |
Parity |
None |
21
|
(14.3)
|
13
|
(8.2)
|
62
|
(12.4)
|
23
|
(4.3)
|
1–3 |
93
|
(63.3)
|
98
|
(61.6)
|
227
|
(45.6)
|
209
|
(38.8)
|
≥ 4 |
32
|
(21.8)
|
47
|
(29.6)
|
205
|
(41.2)
|
306
|
(56.9)
|
Use of contraception at any point at life |
No | 85 | (57.8) | 86 | (54.1) | 294 | (59.0) | 299 | (55.6) |
Yes | 62 | (42.2) | 73 | (45.9) | 202 | (40.6) | 239 | (44.4) |
Use of hormones for menopause for more than 1 month |
No | – | – | – | – | 380 | (76.3) | 456 | (84.8) |
Yes | – | – | – | – | 114 | (22.9) | 81 | (15.1) |
Breastfeeding in monthsb | 9 | 2–25 | 12 | 4–34 | 12 | 1–42 | 24 | 6–57 |
Anthropometry
|
Waist circumference (cm)b,c | 93.3 | 84.8 - 101.5 | 97.7 | 92–107.0 | 97.0 | 90.3–104.8 | 99.5 | 91.65–108.0 |
Hip circumference (cm)b,c | 103.1 | 97.2 - 111.0 | 107.9 | 102 - 115.7 | 106.25 | 100.3–114.6 | 108.0 | 101–117.0 |
Height (cm)b,c | 154.5 | 150.5 - 158.5 | 153.8 | 149.7 - 158.0 | 151.8 | 147.3–156.0 | 150.5 | 146.7–154.4 |
Weight (kg)b,c | 65.8 | 59.5 - 74.2 | 70.2 | 64.0–79.6 | 67.2 | 60.2–76.6 | 67.8 | 60.4–77.4 |
Body mass index (weight in kg/height squared)b,c | 27.4 | 24.9–31.5 | 29.8 | 27.1–33.4 | 29.2 | 26.4–33.2 | 30.2 | 27.1–33.8 |
Waist-hip ratiob,c | 0.90 | 0.86–0.94 | 0.91 | 0.87–0.95 | 0.91 | 0.87–0.96 | 0.91 | 0.87–0.97 |
Silhouette trajectory
|
Group 1, constantly low | 19 | (12.9) | 28 | (17.6) | 76 | (15.3) | 94 | (17.5) |
Group 2, constantly mid-range | 57 | (38.8) | 56 | (35.2) | 199 | (40.0) | 200 | (37.2) |
Group 3, moderate increase | 27 | (18.4) | 32 | (20.1) | 101 | (20.3) | 117 | (21.7) |
Group 4, Strong increase | 41 | (27.9) | 37 | (23.3) | 104 | (20.9) | 113 | (21.0) |
Group 5, constantly high | 3 | (2.0) | 6 | (3.8) | 18 | (3.6) | 14 | (2.6) |
Breast pathology
|
Personal history of benign breast disease |
No | 126 | (85.7) | 140 | (88.1) | 425 | (85.3) | 506 | (94.1) |
Yes | 20 | (13.6) | 16 | (10.1) | 65 | (13.1) | 27 | (5.0) |
Family history of breast cancer (mother, grandmother, and sisters) |
No | 137 | (93.2) | 148 | (93.1) | 466 | (93.6) | 525 | (97.6) |
Yes | 10 | (6.8) | 11 | (6.9) | 32 | (6.4) | 13 | (2.4) |
Lifestyle
|
Hours of moderate-intensity physical activity per weekb,d | 9.0 | 3.5–18.0 | 12.0 | 2.0–25.5 | 5.5 | 1.0–10.5 | 12.0 | 2.0–22.0 |
Consumed on average one or more alcoholic drinks a month for a year |
No | 108 | (73.5) | 139 | (87.4) | 403 | (80.9) | 472 | (87.7) |
Yes | 39 | (26.5) | 18 | (11.3) | 70 | (14.1) | 47 | (8.7) |
Smoked at least 100 cigarettes in her lifetime |
No | 119 | (81.0) | 113 | (71.1) | 370 | (74.3) | 442 | (82.2) |
Yes | 28 | (19.0) | 46 | (28.9) | 128 | (25.7) | 96 | (17.8) |
Daily total consumption of calories (Kcal)b,d | 2262.6 | 1776.1 - 2704.1 | 1853.0 | 1514.8–2302.6 | 2014.9 | 1631.1–2557.1 | 1748.5 | 1396.0–2160.4 |
Comorbidities
|
Diagnosed with diabetes mellitus by a physician |
No | 123 | (84.4) | 130 | (82.4) | 330 | (66.3) | 399 | (74.2) |
Yes | 15 | (10.2) | 18 | (11.3) | 126 | (25.3) | 107 | (19.9) |
Table 2
Thyroid function parameters of study participants by menopausal status in the CAMA study, Mexico, 2004–2007
Thyroid function parameters
|
Total triiodotyronine (TT3) nmol/La | 1.6 | 1.3–1.9 | 2.4 | 1.9–2.8 | 1.7 | 1.4–2.1 | 2.6 | 2.1–3.0 |
Mean (SD) | 1.7 | 0.5 | 2.4 | 0.6 | 1.8 | 0.7 | 2.6 | 0.6 |
Total thyroxin (TT4) nmol/La | 103.4 | 87.4–123.1 | 93.1 | 83.7–109.7 | 104.6 | 89.8–122.3 | 96.7 | 84.4–112.2 |
Mean (SD) | 107.3 | 27.3 | 97.2 | 22 | 108.6 | 29.5 | 100.5 | 25.7 |
TSH μUI/mLa | 1.6 | 1.1–2.1 | 1.7 | 1.1–2.3 | 1.8 | 1.1–2.8 | 1.8 | 1.1–2.9 |
Mean (SD) | 1.8 | 1.4 | 2.3 | 3.3 | 2.9 | 9.6 | 2.9 | 6.8 |
Thyroglobulin ng/mLa | 6.4 | 4.0–10.2 | 7.1 | 4.5–12.2 | 7.4 | 3.9–14.5 | 7.4 | 4.0–14.5 |
Mean (SD) | 8.9 | 9.3 | 9.9 | 10.9 | 17.8 | 70.1 | 15.9 | 47.1 |
Anti-peroxidase antibodies UI/mLb | 0.1 | 0.5–2.5 | 1.10 | 0.6–3.1 | 1.1 | 0.6–3.9 | 1.1 | 0.6–3.5 |
Mean (SD) | 46.4 | 266.2 | 222.3 | 1373.8 | 111.1 | 444.6 | 95.0 | 346.3 |
Anti-thyroglobulin antibodiesb,c |
Negative | 73 | (49.7) | 59 | (37.1) | 135 | (27.1) | 133 | (24.7) |
Positive | 71 | (48.3) | 100 | (62.9) | 221 | (44.4) | 240 | (44.6) |
Median UI/mL (interquartile range)d | 0.9 | 0.3–3.1 | 1.0 | 0.04–3.0 | 1.0 | 0.3–4.6 | 0.8 | 0.4–2.8 |
Mean (SD)d | 17.7 | 106.4 | 4.7 | 9.8 | 23.1 | 165.1 | 14.4 | 102.4 |
Table 3
Clinical characteristics of patients with breast cancer (cases) by menopausal status in the CAMA study, Mexico, 2004–2007
Clinical characteristics
|
Clinical stage |
Early (≤ IIA) | 43 | (29.3) | 175 | (35.1) |
Advanced (≥ IIB) | 73 | (49.7) | 206 | (41.4) |
Histological grade |
1 | 4 | (2.7) | 8 | (1.6) |
2 | 29 | (19.7) | 108 | (21.7) |
3 | 9 | (6.1) | 49 | (9.8) |
In the premenopausal women who were stratified by tertiles of the anthropometric variables (BMI, waist and hip measurements, and WHR), the median serum TT3 concentration was lower in the patients than in the controls, whereas TT4 concentrations were higher in the patients than in the controls, and serum TSH concentrations were similar in both groups. The same relationship was observed in postmenopausal women (data not shown).
Multiple models, minimally adjusted for age, health institution, and city of residence, showed that when all the women were analyzed, the serum concentration of the TT3 hormone was negatively associated with BC (OR per standard deviation = 0.16, 95% CI 0.13–0.20), and this association was maintained when the patients were stratified into the premenopausal (OR per standard deviation = 0.07, 95% CI 0.04–0.12) and postmenopausal groups (OR per standard deviation = 0.20, 95% CI 0.16–0.25) (data not shown). However, the protective effect was much higher in premenopausal than in postmenopausal women. The association between serum TT4 concentration and BC was positive when all the women were analyzed (OR per standard deviation = 1.71, 95% CI 1.48–1.98), and this association was maintained when the patients were stratified by menopausal status; however, stronger association was seen in premenopausal women (OR per standard deviation = 1.97, 95% CI 1.38–2.82) compared with postmenopausal women (OR per standard deviation = 1.71, 95% CI 1.48–1.98) (data not shown). No significant associations were found with any other thyroid function parameters (TSH, Tg, Tg Ab, or TPO Ab).
Table
4 presents the multiple model stratified by menopausal status, adjusted by BMI and Table
5 presents the models stratified by both menopausal status and BMI. In Table
4, a negative association was observed between the serum TT3 concentration and BC in both premenopausal and postmenopausal women, and a positive association was observed between the serum TT4 concentration and BC. The association was stronger in premenopausal women than in postmenopausal women for both hormones. These associations were similar when each of the remaining anthropometric variables and the trajectory of the silhouettes were independently adjusted (Additional file
1: Table S1).
Table 4
Associations between thyroid function tests and breast cancer adjusted by BMI in the CAMA study, Mexico, 2004–2007
TT3c | 128/142 | 0.03 | 0.01–0.07 | 382/498 | 0.17 | 0.13–0.22 |
TT4c | | 5.98 | 3.01–11.90 | | 2.81 | 2.17–3.65 |
BMI |
Tertile 1 (BMI < 27.88) | 67/47 | 1.00 | | 145/166 | 1.00 | |
Tertile 2 (BMI 27.88–32.05) | 35/48 | 0.56 | 0.23–1.37 | 106/168 | 0.98 | 0.63–1.52 |
Tertile 3 (BMI ≥ 32.06) | 26/47 | 0.28 | 0.11–0.75 | 131/164 | 1.16 | 0.75–1.80 |
Table 5
Association between thyroid function tests and breast cancer modified by obesity in the CAMA study, Mexico, 2004–2007
Multiple model stratified by BMI tertiles |
Tertile 1 (BMI < 27.88) | 67/47 | | | 145/166 | | |
TT3c | | 0.02 | 0.003–0.09 | | 0.18 | 0.11–0.28 |
TT4c | | 11.97 | 3.43–41.80 | | 2.62 | 1.67–4.09 |
Tertile 2 (BMI 27.88–32.05) | 35/48 | | | 106/168 | | |
TT3c | | 0.04 | 0.0 –0.16 | | 0.15 | 0.09–0.25 |
TT4c | | 8.34 | 2.03–34.24 | | 3.03 | 1.83–5.02 |
Tertile 3 (BMI ≥ 32.06) | 26/47 | | | 131/164 | | |
TT3c | | 0.01 | 0.0004–0.08 | | 0.10 | 0.06–0.18 |
TT4c | | 2.23 | 0.39–12.66 | | 3.52 | 2.15–5.75 |
p value for interaction between TT4 and BMI tertiles | | 0.22 | | | 0.059 |
p value for interaction between TT3 and BMI tertiles | | 0.12 | | | 0.34 |
When premenopausal women were stratified by BMI (Table
5), it was observed that the association between the serum concentration of TT4 and BC decreased as BMI tertiles increased, until they were no longer significant in the upper tertile (
p of interaction = 0.22), while the protective effect of the serum TT3 concentration was maintained in the three tertiles (
p of interaction = 0.12). Similarly, the effects of the serum concentrations of TT3 and TT4 were evaluated based on the remainder of the anthropometric variables, and waist circumference (
p = 0.887), hip circumference (
p = 0.291), WHR (
p = 0.381), and the silhouettes trajectory variable (
p = 0.52) were not statistically significant (Additional file
1: Table S2). In postmenopausal women, stratification by BMI showed that the association between the serum TT4 concentration and BC increased as the BMI tertiles increased (
p of interaction = 0.059) (Table
5). For the other anthropometric variables, potential effect modification was observed with hip circumference (tertile 1, OR = 2.17, CI 1.34–3.50; tertile 2, OR = 3.58. CI 2.16–5.95; tertile 3, OR = 3.47, CI 2.12–5.68,
p of interaction = 0.02), with WHR (tertile 1, OR = 2.97, CI 1.84–4.80; tertile 2, OR = 4.43. CI 2.38–8.27; tertile 3, OR = 2.46, CI 1.60–3.80,
p of interaction = 0.02), and with the silhouettes trajectory (constantly low, OR = 3.87, CI 1.72–8.73; constantly mid-range, OR = 2.12, CI 1.44–3.13; moderately increased, OR = 2.53, CI 1.37–4.66; strong increase, OR = 4.57, CI 2.38–8.86,
p of interaction = 0.02), but an effect modification was not observed with waist circumference (p of interaction = 0.51). The interactions between the serum TT3 concentration and the anthropometric variables were also evaluated, but these were not statistically significant for BMI (
p = 0.34), hip circumference (
p = 0.49), waist circumference (
p = 0.74), WHR (
p = 0.38), or the silhouettes trajectory (
p = 0.36) (Additional file
1: Table S2).
Discussion
The addition of T4 to BC-derived cell lines has been shown to increase cell proliferation [
3], while in the presence of estrogen receptor (ER)-positive BC cell lines the addition of T3 inhibits cell proliferation [
7]. These effects are important, as abnormalities in thyroid function tests have been observed in a variety of nonthyroidal illness, without preexisting thyroid or hypothalamic-pituitary disease, including BC [
80]. These abnormalities might change by BMI because thyroid hormones are involved in the regulation of various metabolic pathways that are relevant for resting energy expenditure [
10,
11]. They could also change by menopausal status because obesity has been negatively associated with BC in premenopausal women [
20‐
27] and has been positively associated with BC in postmenopausal women [
30]. It is important to assess the modifying effect of obesity in this association because of the implications for treatment in populations in where the prevalence of obesity and thyroid dysfunction is high.
We analyzed the association between thyroid hormones and BC and the modification effects of general obesity (BMI), central or intra-abdominal obesity (waist circumference, hip circumference, and waist-hip ratio), and trajectories of change in body shape. Initially, we observed that in both the premenopausal and postmenopausal women, the serum TT4 concentration was positively associated with BC, whereas the serum TT3 concentration was inversely associated with BC. These associations were stronger in the premenopausal women. When the premenopausal women were stratified by BMI tertiles, the positive association between the serum TT4 concentration and BC decreased as the BMI tertiles increased; this association was no longer statistically significant in the highest tertile, probably due to the smaller sample size. In contrast, for the postmenopausal women in the highest tertile of BMI, the strength of the association between the serum TT4 concentration and BC was increased.
A possible explanation for our findings could be related to the difference between premenopausal and postmenopausal women with respect to the possibility or risk of the development of ER-negative (ER-) BC due to BMI [
81] and due to the finding that the maintenance of increased cell proliferation caused by T4 requires ER function [
82]. Studies that have investigated the association between BMI and different molecular subtypes have suggested that in premenopausal women with a BMI ≥ 25, the prevalence of luminal tumors (ER positive (ER+) or progesterone receptor-positive (PR+)), human epidermal growth factor receptor 2 positive or negative (HER2+ or HER2-) and triple-negative tumors (ER-, PR-, HER2-) is higher than in those with a BMI < 25 [
83]. Harris et al. (2011) consistently showed that in this same group of women, the risk of development of ER- BC was higher in those in the upper quintiles of waist and hip circumference and of WHR than in those in the lower quintile [
27]. In contrast, in postmenopausal women, compared with women with a BMI < 25, the possibility of the development of luminal BC was greater in those with a BMI ≥ 25 [
83]. Additionally, a pooled analysis of 35,568 women with invasive BC who participated in 34 studies showed that in those ≤ 50 years of age, the likelihood of observing ER- tumors was higher in obese women (BMI ≥ 30 kg/m
2) than in women who were not obese (BMI < 25 kg/m
2), and this association was statistically significant [
81]. This same association was not statistically significant in women > 50 years of age [
81].
Tang et al. observed that both the T4 hormone and 17β-estradiol (E2) promoted cell proliferation through the stimulation of the mitogen-activated protein kinase (MAPK) pathway by ER and demonstrated that such proliferation requires ER function to be sustained [
82]. In several cell models, it has been observed that at physiological concentrations, T4 is more active than T3 at stimulating the MAPK pathway [
84‐
87]. In premenopausal women, the decrease in the association between TT4 and BC with increasing BMI could be explained by the lower prevalence of ER+ tumors in overweight and obese women [
88,
89]. In contrast, in postmenopausal women, the increase in the association between T4 and BC with increasing BMI may be explained by the finding that overweight and obese women are at a greater risk of the development of ER+ breast tumors. However, more studies need to be performed stratifying by menopausal status and BMI. Two cohort studies reported a positive association between the serum T4 concentration and BC. However, in the aforementioned studies no effect modification was assessed for BMI and menopausal status [
1,
90].
In our study we observed a negative association between serum TT3 and BC in both premenopausal and postmenopausal women. On the other hand, we did not observe an effect modification of this association by BMI. In addition, our results are consistent with previously published studies. For example, in studies of ER- cell lines that were transfected with ER, T3 inhibited cell proliferation [
7]. Also, Tosovic et al., reported a non-statistically significant negative association between serum T3 and BC, independently of menopausal status [
1]. That group also observed a negative association when women were stratified by menopausal status and BMI; however, it was not statistically significant [
1].
The findings that we report need to be interpreted within the context of certain limitations. The number of premenopausal women was not sufficient for the identification of a statistically significant effect modification by BMI or other obesity measurements; moreover, the confidence intervals after stratification were broad, particularly for other anthropometric measurements that are presented in additional tables. Given the characteristics of Mexican women, among whom more than 70% were overweight and obese, it was not possible to use the cutoff points proposed by the WHO for anthropometric measurements; hence, we stratified the controls by tertiles for each measurement. Our study personnel were trained to measure weight and height and the other anthropometric variables using a standardized approach in both cases and controls, and in the cases, the measurements were performed at the time of the diagnosis. As BMI can be modified by the presence of cancer, this study is not free of reverse causality. However, the median number of days from the diagnosis until the women entered the study and the anthropometric variables were determined was 3 days. Additionally, we measured TT4. Free T4 (FT4) is unbound and is the active component of TT4, therefore further studies should be performed using FT4. Approximately 75% of the T4 in serum is bound to thyroid-binding globulin (TBG), and a smaller fraction is bound to transthyretin or albumin; so less than 0.1% remains free or unbound [
91]. Given that postmenopausal hormone therapy and the use of hormonal contraceptives at any point in life lead to increased thyroid binding globulin (TBG) binding capacity [
92], we considered adjusting for these variables in our models. However, we did not include them in the final models because they did not confound our main results. We did not include the ER status because when recruiting the patients (cases), ER status was not determined in all women. Tosovic et al., (2014) found statistically significant positive associations between higher pre-diagnostic T3 concentration and negative ER status [
93]. However, further analysis needs to be performed because the sample size was very small and they did not adjust or stratify by BMI.
Our findings are congruent with previously observed altered T3 and T4 measurements in diseases such as BC [
9]. In those circumstances, there is dysregulation of thyrotrophic feedback control [
9], in which T3 and/or T4 are at unusual levels, but the thyroid gland does not appear to be dysfunctional. Thus, the lower levels of T3 and higher levels of T4 in BC cases may be due to the effect of BC on thyroid function rather than T3 and T4 acting as risk factors for BC. If so, these findings may still be of interest to understand whether the levels of T3 and T4 could be related to tumor stage or have other implications for prognosis.
Our findings need to be replicated in other studies, including those with larger sample sizes and to investigate other possible mechanisms by which the association between T4 and BC is potentially modified by BMI in premenopausal and postmenopausal women. In particular, prospective cohort studies in which T3 and T4 are collected prior to cancer diagnosis may be helpful in understanding the causal relationship between BC and thyroid hormones. In addition, a prospective study may also help to improve understanding of the relationship among thyroid hormones, BC, and obesity.
To the best of our knowledge, this is the first study that has evaluated the effect modification by BMI of the relationship between thyroid hormones and BC, both in premenopausal and postmenopausal women. The results of the present study open a new line of research with which to evaluate the effect modification by obesity of the association between thyroid hormones and BC.
Acknowledgments
We would like to acknowledge CONACyT (CONACyT-SALUD-2002 C01-7462) y DGPOP 2011 (Dirección General de Programación Organización y Presupuesto, Ejercicio fiscal 2011, Ramo 12 Salud) for the financial support provided for this work and all physicians responsible for the project in the different participating hospitals: Dr Germán Castelazo (IMSS, Ciudad de México, DF), Dr Sinhué Barroso Bravo (IMSS, Ciudad de México, DF), Dr Joaquín Zarco Méndez (ISSSTE, Ciudad de México, DF), Dr Jesús Pablo Esparza Cano (IMSS, Monterrey, Nuevo León), Dr Heriberto Fabela (IMSS, Monterrey, Nuevo León), Dr Fausto Hernández Morales (ISSSTE, Veracruz, Veracruz), Dr Pedro Coronel Brizio (CECAN SS, Xalapa, Veracruz) and Dr Vicente A Saldaña Quiroz (IMSS, Veracruz, Veracruz).